Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
08/2010
08/11/2010CN101039930B 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
08/11/2010CN101024002B Oral Chinese medicine composition for treating hypertension
08/10/2010US7772260 Neuroprotectants; reduce side effect of neurotoxic agent; treatment of neuropathies resulting from chemotherapeutic agents used in the treatment of HIV and proliferative disease such as cancer and treatment of inflammatory diseases, neurodegenerative diseases
08/10/2010US7772249 Imidazo[1,2-b]pyridazine compound
08/10/2010US7772247 vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) receptor antagonists such as 1-(4-(2-(N-methoxy-N-methylcarbamoyl)thieno[3,2-b]pyridin-7yloxy)-3-fluorophenyl)-3-(2-phenylacetyl)thiourea, used as antiproliferative agents
08/10/2010US7772229 Oxabispidine compounds useful in the treatment of cardiac arrhythmias
08/10/2010US7772226 such as 3-(2-Butynyl)-2-(piperazin-1-yl)-3,5-dihydroimidazo[4,5-d]pyridazin-4-one trifluoroacetate, used as dipeptidyl peptidase-IV (DPPIV) inhibitors for the treatment of obesity and diabetes
08/10/2010US7772001 Determining preferential gene expression pattern in embryonic cells; obtain cells, monitor gene expresion products, incubate with animal growth regulators, monitor gene expresion pattern and differentiation in cells
08/10/2010US7771979 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
08/10/2010US7771931 Using presence of allelic mutation in protein kinase c gene as diagnostic indication of heart disease
08/10/2010US7771748 Reducing smoking; side effect reduction
08/10/2010US7771744 Bazedoxifene acetate formulations
08/10/2010US7771739 Implantable medical devices comprising semi-crystalline poly(ester-amide)
08/10/2010CA2488592C 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
08/10/2010CA2471147C Nitric oxide donors for treatment of disease and injury
08/10/2010CA2467013C Substituted benzopyrans as selective estrogen receptor-beta agonists
08/10/2010CA2451605C Diamine derivatives
08/10/2010CA2451452C Cyclic diamine compound with condensed-ring groups
08/10/2010CA2440714C Pyrazolopyrimidines as therapeutic agents
08/10/2010CA2391832C Oral dosage forms
08/10/2010CA2389647C Isoxazole derivatives as phosphodiesterase vii inhibitors
08/10/2010CA2366800C Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
08/10/2010CA2361617C Uses of thank, a tnf homologue that activates apoptosis
08/10/2010CA2249542C Pyrazole derivatives, their preparation and their use in pharmaceuticals
08/10/2010CA2237099C Sulfonylaminocarboxylic acids
08/10/2010CA2223491C Cdr-grafted anti-tissue factor antibodies and methods of use thereof
08/05/2010WO2010088455A2 Cromolyn derivatives and related methods of imaging and treatment
08/05/2010WO2010088450A2 Methods for treating diseases associated with the modulation of serca
08/05/2010WO2010088392A1 Carboxamide compounds and methods for using the same
08/05/2010WO2010088195A1 Azaquinazolinediones useful as chymase inhibitors
08/05/2010WO2010087515A1 Fused ring compound and use thereof
08/05/2010WO2010087454A1 Quinoline derivative
08/05/2010WO2010087399A1 Urotensin-ii receptor antagonists
08/05/2010WO2010087315A1 Anti-alzheimer’s disease agent
08/05/2010WO2010087313A1 Neurite elongation stimulator
08/05/2010WO2010087244A1 Cyclic amino alcohol compound
08/05/2010WO2010087150A1 Gastric acid secretion inhibitor, and potassium channel inhibitor
08/05/2010WO2010086646A1 Scriptaid isosteres and their use in therapy
08/05/2010WO2010086454A1 N-(phenyl or pyridyl)prenylamine derivatives for the treatment of obesity, diabetes, cardiovascular diseases and other adiponectin-related diseases
08/05/2010WO2010086403A1 Azetidines as histamine h3 receptor antagonists
08/05/2010WO2010086384A1 Target for treatment of acute heart failure
08/05/2010WO2010086382A1 Target for treatment of acute heart failure
08/05/2010WO2010086280A1 Novel n-oxides of furanyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
08/05/2010WO2010086278A1 Novel benzodioxolyl-oxadiazolyl-diazabicyclononane derivatives and their medical use
08/05/2010WO2010066931A4 Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug
08/05/2010WO2010063470A3 Methods for preventing or reducing colon carcinogenesis
08/05/2010WO2010055119A3 Pharmaceutical composition comprising pimobendan
08/05/2010WO2009143944A3 Treatment of thromboangiitis obliterans by removal of autoantibodies
08/05/2010WO2008091867A3 Periostin induces proliferation of cardiomyocytes and promotes cardiac regeneration
08/05/2010WO2003060149A9 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/05/2010US20100197917 Coumarin derivatives useful as tnf alpha inhibitors
08/05/2010US20100197911 Nitrogen-Containing Aromatic Derivatives
08/05/2010US20100197907 Phosphorus-containing compounds & uses thereof
08/05/2010US20100197803 Method for obtaining a sequoyitol-containing extract from a plant of the genus of trifolium, leguminosae or ginkoaceae and uses thereof
08/05/2010US20100197793 Solid state forms of aliskiren compounds
08/05/2010US20100197785 Omega-3 fatty acid fortified composition
08/05/2010US20100197779 Phytoestrogenic isoflavone compositions, their preparation and use thereof for protection against and treatment of radiation injury
08/05/2010US20100197764 Antisense modulation of acyl coa cholesterol acyltransferase-2 expression
08/05/2010US20100197744 Organic Compounds
08/05/2010US20100197736 Cetp activity inhibitors
08/05/2010US20100197731 kind of piperphentonamine hydrochloride lyophilized powder for injection and preparation and use thereof
08/05/2010US20100197725 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof
08/05/2010US20100197716 N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
08/05/2010US20100197714 Spiro-pyrano-pyrazole derivatives
08/05/2010US20100197710 Methods Of Activating IRS-1 And AKT
08/05/2010US20100197709 Non-sedating barbiturate compounds as neuroprotective agents
08/05/2010US20100197707 Platelet manipulation to reduce the incidence of and treat endovascular disease and its sequelae, to reduce the incidence of and treat arrhythmias and to reduce the incidence of malignancy
08/05/2010US20100197693 Novel benzenesulfonamides as calcium channel blockers
08/05/2010US20100197692 Bicyclic heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
08/05/2010US20100197688 Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
08/05/2010US20100197684 Substituted heterocyclic compounds
08/05/2010US20100197683 Fused ring compound and use thereof
08/05/2010US20100197681 Triazolopyridine Compounds and Their Use as Ask Inhibitors
08/05/2010US20100197680 Lactam-substituted dicarboxylic acids and use thereof
08/05/2010US20100197657 2-aryl or heteroaryl indole derivatives
08/05/2010US20100197630 Cetp inhibitors derived from benzoxazole arylamides
08/05/2010US20100197623 Anti-Infammatory Macrolide
08/05/2010US20100197609 Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
08/05/2010US20100197608 Use of melanotrophin-potentiating factor as a therapeutic agent
08/05/2010US20100197605 Therapeutic use of peptide yglf and combination with kvlpvpq
08/05/2010US20100197604 Use of peptide as a therapeutic agent
08/05/2010US20100197602 Use of follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumoniae infection
08/05/2010US20100197601 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
08/05/2010US20100197600 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
08/05/2010US20100197599 Use of a peptide as a therapeutic agent
08/05/2010US20100197588 Use of a peptide as a therapeutic agent
08/05/2010US20100197587 Use of a peptide as a therapeutic agent
08/05/2010US20100197586 Use of secretin and optionally urodilatin as therapeutic agents
08/05/2010US20100197585 Use of a rgd-peptide and/or parathyroid hormone (1-34) as anti-hiv agent
08/05/2010US20100197580 Parstatin peptides and uses thereof
08/05/2010US20100197574 Aquaretic and natriuretic polypeptides lacking vasodilatory activity
08/05/2010US20100197572 Use of somatostatin-14 as a therapeutic agent
08/05/2010US20100197564 Diaryl morpholines as cb1 modulators
08/05/2010US20100197562 Functionally selective alpha2c adrenoreceptor agonists
08/05/2010US20100196496 Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
08/05/2010US20100196488 Pharmaceutical Formulation
08/05/2010US20100196475 Controlled release tablet formulation containing magnesium aluminometasilicate
08/05/2010US20100196472 Modified release compositions of milnacipran
08/05/2010US20100196471 Novel tablet dosage form
08/05/2010US20100196469 Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof
1 ... 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 ... 1595